AIM: To determine whether peak flow rate (PFR) and post-void residual urinary volume (PVRUV) predict prostate biopsy outcome.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
PATIENTS AND METHODS: The study population consisted of 1780 patients undergoing first prostate biopsy.
RESULTS: Patients with prostate cancer (PCa) had significantly greater prostate-specific antigen (PSA) and PFR but lower prostate volume (PVol) and PVRUV than those without PCa. Receiver operator characteristic curve analysis showed that PVol and PVRUV were the most accurate predictors of biopsy outcome. The addition of PVRUV to the multivariate logistic regression model based on standard clinical parameters (age, PSA, digital rectal examination, PVol) significantly increased the predictive accuracy of the model in both the population overall (79% vs. 77%; p=0.001) and patients with PSA levels up to 10 ng/ml (74.3% vs. 71.7%; p=0.005).
CONCLUSION: PVRUV seems to be an accurate non-invasive test to predict biopsy outcome that can be used alone or in combination with PVol in the decision-making process for men potentially facing a prostate biopsy.
Cormio L, Lucarelli G, Netti GS, Stallone G, Selvaggio O, Troiano F, DI Fino G, Sanguedolce F, Bufo P, Grandaliano G, Carrieri G. Are you the author?
Department of Urology and Renal Transplantation, University of Foggia, Foggia, Italy; Department of Clinical Pathology, University of Foggia, Foggia, Italy; Department of Nephrology Dialysis and Transplantation; Pathology, University of Foggia, Foggia, Italy.
Reference: Anticancer Res. 2015 Apr;35(4):2175-82.